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Lymphangiogenesis in cancer, 
inflammation, and tissue 
remodeling
Lymphatic vessels are common routes for 
tumor cell metastasis, and sentinel lymph 
node metastasis is a major prognostic 
indicator of breast cancer outcome. Since 
the identification of lymphatic-specific 
growth factors VEGF-C and VEGF-D and 
their receptor VEGFR-3, numerous studies 
have demonstrated striking correlations 
between tumor-associated lymphangio-
genesis, or peritumoral lymphatic expan-
sion, and metastasis (1). Originally the 
correlation between lymphangiogenesis 
and tumor metastasis was attributed to 
increased accessibility for tumor cell dis-
semination, but recent studies have shown 
that tumor-associated lymphangiogenesis 
provides many immune-suppressive fea-
tures to the tumor microenvironment and 
can pacify tumor-specific cytotoxic T lym-
phocytes as well as drive deletional toler-
ance of naive T cells (2, 3).
On the other hand, lymphangiogen-
esis is not specific to the tumor microen-
vironment and generally accompanies all 
types of inflammation, particularly in late 
or chronic stages, including chronic infec-
tions, wound healing and tissue remod-
eling, autoimmune diseases like Crohn’s 
disease, and the resolution phase of acute 
inflammation (3, 4). Lymphangiogenesis 
is driven by a host of inflammatory cells 
that secrete VEGF-C, including mast cells, 
neutrophils, macrophages, activated stro-
mal cells, angiogenic blood endothelium, 
and B cells (3). These cells can upregulate 
their production of VEGF-C or VEGF-D 
upon exposure to prostaglandin E2 (PGE2), 
which plays many important and complex 
roles in the tumor microenvironment. 
Overall, cyclooxygenase-2–driven (COX-2– 
driven) PGE2 upregulation is thought to 
help control cytotoxic immune responses 
in later stages of inflammation; as such, it 
is also expressed in chronic infection and 
autoimmunity (5). The major actions of 
COX-2–dependent PGE2 expression on 
leukocytes and stromal cells tend to be 
suppressive, and in the tumor microenvi-
ronment, this pathway drives development 
of myeloid-derived suppressor cells, regu-
latory T cells, and alternatively activated 
macrophages. In dendritic cells, PGE2 
upregulates suppressive factors, like IL-10 
and indoleamine 2,3-dioxygenase (IDO), 
leading to dysfunctional T cell activa-
tion. Therefore, since these inflammatory 
events in the tumor microenvironment 
are coincident with lymphangiogenesis, 
teasing out the mechanisms by which 
lymphangiogenesis specifically contributes 
to cancer metastasis is inherently difficult.
Function and consequences 
of inflammatory 
lymphangiogenesis
During inflammation, lymphangiogenesis 
often involves hyperplasia of preexisting 
lymphatic vessels, increased vessel diam-
eters, and decreased organization and 
patterning. The expanded lymphatic net-
work in inflamed tissues often resembles 
the vascular plexus of the liver sinusoids 
or bone marrow vasculature. It remains 
controversial whether these altered ves-
sels have increased transport functions — 
draining fluid or carrying cells to the lymph 
node — but several recent studies have sug-
gested other functions of lymphatic expan-
sion. First, as mentioned above, VEGF-C 
and VEGF-D are triggered in later stages 
of inflammation. PGE2 is a key driver of 
inflammatory lymphangiogenesis through 
its actions on inflammatory cells that 
secrete VEGF-C and VEGF-D. Moreover, 
upregulation of PGE2 is considered to be 
key for the resolution of inflammation and 
dampening cytotoxic immune responses; 
therefore, the activated lymphatic endo-
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Like many cancers, mammary carcinomas use lymphatic vessels to 
disseminate, and numerous clinical and experimental studies have 
documented a strong correlation between peritumoral lymphangiogenesis 
and tumor dissemination. At the same time, many other factors can affect 
the incidence, invasiveness, and mortality of breast cancer, including 
lactation history. Although lactation reduces overall cancer risk, patients 
diagnosed within 5 years of pregnancy have an increased incidence 
of metastatic disease. In this issue of the JCI, Lyons and colleagues 
demonstrate that postpartum breast tissue remodeling during involution 
coincides with inflammatory lymphangiogenesis. In mouse models, 
cyclooxygenase-2 (COX-2) inhibition during involution reduced the risk 
of cancer metastasis and correlated with decreased lymphangiogenesis. 
In addition to lymphangiogenesis, COX-2 inhibition reduces many of the 
immune-suppressive features of the tumor microenvironment, including 
development of myeloid-derived suppressor cells and regulatory T cells; 
therefore, these results support the notion that inhibiting COX-2 during 
lactation weaning may lessen the incidence of breast cancer metastasis.
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inflammatory cells drive lymphangiogene-
sis, lymphangiogenesis also alters the local 
immune cell repertoire.
It was first suggested a decade ago 
that COX-2 could drive inflammatory or 
tumor-associated lymphangiogenesis. 
At this time, activation of the E-prost-
hyperplasia could therefore increase the 
relative importance of these functions by 
increasing LEC surface area. Finally, VEG-
F-C triggers LECs to upregulate CCL21 
(6), a lymphoid homing chemokine that 
attracts not only dendritic cells and naive T 
cells but also regulatory T cells. Thus, while 
thelium likely serves immune-suppressive 
roles in such an environment. Second, lym-
phatic endothelial cells (LECs) have been 
shown to suppress dendritic cell matura-
tion, secrete suppressive cytokines and fac-
tors like IDO, and directly activate naive T 
cells for deletional tolerance (3); lymphatic 
Figure 1. PGE2 is involved in later stages of inflammation and promotes immune-suppressive cell types and lymphangiogenesis through complex and 
interacting pathways. (A) Common features of the inflammatory microenvironment found in tissue remodeling, wound healing, chronic inflammation, 
and cancer. Alternatively activated or M2-like macrophages, fibroblasts, epithelial cells, myeloid-derived suppressor cells (MDSCs), and mast cells are 
among the sources of COX-2 that drive PGE2 production. PGE2 drives the upregulation of lymphangiogenic growth factors VEGF-C and VEGF-D by several 
cell types, including monocytes, mast cells, macrophages, fibroblasts, and tumor cells. PGE2 also suppresses both innate and adaptive immune responses 
through multiple actions, including differentiation of regulatory T cells, suppression of NK cells, and skewing of dendritic cell (DC) phenotypes toward 
regulatory dendritic cells, which together with monocytes, myeloid-derived suppressor cells, and M2-like macrophages secrete immune-suppressive 
factors like IL-10, TGF-β, and IDO. Together, these immune-suppressive features of the PGE2-rich inflammatory microenvironment are critical for resolving 
inflammation, wound repair, and tissue remodeling (including during mammary gland involution) and for restoring tissue homeostasis and function while 
avoiding unwanted autoimmune responses; on the other hand, the same features promote immune escape of malignant cells and thus promote cancer 
and metastasis. (B) The breast tissue undergoes drastic remodeling during involution and is populated by immune-suppressive cell types and cytokines 
that help drive lymphangiogenesis. Inhibiting COX-2 during involution may help suppress or prevent this inflammatory microenvironment and therefore 
risk of metastatic breast cancer in some women, but it remains unknown how inhibiting COX-2 will affect normal involution and restoration of the mam-
mary gland to a homeostatic state. mDC, mature dendritic cell; iDC, immature dendritic cell. 
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of this notion, COX-2 inhibition during 
involution both blocked lymphangiogenesis 
and prevented metastasis in murine mod-
els. These exciting findings provide further 
rationale for antiinflammatory treatment 
during lactation weaning.
Many questions remain and will need 
to be addressed before therapeutic strate-
gies can be designed and clinically imple-
mented. First, how is the normal physio-
logical process of involution affected by 
inhibiting the inflammatory processes 
that drive this remodeling? Can involu-
tion proceed normally if COX-2 is inhib-
ited, and would the resulting breast return 
to a normal quiescent state? Second, as 
lymphangiogenesis and other COX-2–
driven events contribute immune-sup-
pressive functions in the tissue, would 
autoimmune reactions be a risk of attenu-
ating this program?
Finally, it will be important to deter-
mine whether lymphangiogenesis actually 
drives the more invasive breast cancer in 
these patients or merely correlates with 
the inflammation that supports its onset. 
Would specifically blocking lymphangio-
genesis during this weaning period give 
the same efficacy as more generally inhib-
iting all COX-2–dependent inflammatory 
processes? Lymphangiogenesis can be 
inhibited specifically by antibody-medi-
ated blockade of VEGFR-3, which prevents 
LEC proliferation but does not destroy pre-
existing lymphatic vessels (19). Such inhib-
itors have been widely shown in mouse 
models to prevent metastasis, although 
their effects on the overall tumor immune 
microenvironment are poorly understood. 
Such function-blocking antibodies might 
also be interesting potential targets in the 
prophylactic context of the targeted win-
dow during involution.
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Lactation, involution, and 
breast cancer
Among the many risk factors in meta-
static breast cancer are pregnancy and 
lactation history due to the important 
changes induced both hormonally as well 
as physically in the breast tissue. In mul-
tiple studies and meta-analyses, lactation 
has been correlated with reduced breast 
cancer risk, especially in genetically pre-
disposed women (15). On the other hand, 
cancers that develop in women within 5 
years of childbirth have an increased risk 
of metastasis and mortality compared 
with those that develop later. When lacta-
tion ends, dramatic changes in the breast 
occur to remodel the milk-producing ducts 
back into a quiescent state in a process 
termed involution. This remodeling of the 
breast tissue has been a major focus of the 
Schedin lab, who demonstrated previously 
that various features of the inflammatory 
environment accompanying involution 
drive cancer susceptibility and in particu-
lar promote more invasive and prometa-
static cancer development in rodents (16, 
17). Specifically, these features include col-
lagen remodeling, which contributes to a 
stiffer extracellular matrix, an established 
risk factor for disease (18); alternatively 
activated macrophages, which promote 
immune suppression; and COX-2 expres-
sion, which drives the synthesis of PGE2 
that in turn affects the immune microen-
vironment in the many ways described 
above. Based on these results, the Schedin 
group has suggested that inhibiting inflam-
mation during the involution period, for 
example, with NSAIDs, may constitute a 
window of opportunity to prevent met-
astatic breast cancer by preventing the 
resulting collagen synthesis and immune-
suppressive features that are known to 
drive cancer progression.
In this issue, Lyons et al. take this notion 
one step further and demonstrate that 
lymphangiogenesis accompanies the tissue 
remodeling that occurs during postpartum 
mammary duct involution, a process that 
requires PGE2 (10). Because lymphangio-
genesis is part of the inflammatory remod-
eling program, the results of Lyons and 
colleagues suggest that pharmacological 
inhibition of PGE2 signaling during the invo-
lution period could potentially help prevent 
postpartum metastatic breast cancer by 
inhibiting lymphangiogenesis. In support 
anoid receptor 1 (EP1) was reported to 
upregulate VEGF-C in tumor cell lines 
that overexpressed COX-2 (7), and COX-
2 expression was positively correlated 
with VEGF-C expression and lymphatic 
vessel density in human specimens of 
lung and breast cancer (7, 8). Different EP 
receptors have been implicated in COX-
2–driven lymphangiogenesis, depend-
ing on the cell type and model used. The 
diversity of identified EP receptors is not 
surprising given the host of cell types in 
the tumor microenvironment (including 
tumor cells themselves) that can express 
prostaglandin receptors as well as secrete 
VEGF-C and VEGF-D. For example, in 
human lung and breast cancer cell lines, 
COX-2 overexpression has been shown 
to stimulate endogenous PGE2-mediated 
EP1 and EP4 signaling to drive upregula-
tion of VEGF-C and VEGF-D directly by 
the tumor cells (7, 9). In this issue, Lyons 
et al. report that expression of PGE2 by 
postpartum tumor cells stimulates LECs 
directly in an EP2-dependent manner 
(10), although other studies of tumor-as-
sociated stroma implicate EP3 (11, 12). 
In human prostate cancer, EP3 protein 
levels were positively correlated with 
lymphatic vessel density (11), and COX-
2–overexpressing Lewis lung carcinomas 
drove stromal cell secretion of VEGF-C 
via EP3 activation (12). Therefore, PGE2-
mediated tumor lymphangiogenesis is 
complex (13), involving many cell types 
and EP receptors that likely participate in 
much cross-talk (Figure 1).
In summary, emerging evidence sug-
gests that lymphangiogenesis is a normal 
part of the inflammatory cycle and con-
stitutes one of many components that 
serve to return tissues to a normal state 
of homeostasis after inflammation or 
remodeling. Immune-suppressive fea-
tures of such an environment are neces-
sary to avoid local autoimmune reactions 
and resolve the inflammation. The recent 
discovery that LECs can scavenge and 
cross-present exogenous antigen for T cell 
deletion (2, 14) is consistent with a role for 
these cells in restoration of tissue homeo-
stasis and prevention of autoimmunity. 
Finally, because tumors induce a microen-
vironment with hallmarks of immune-sup-
pressive chronic inflammation, it is likely 
that tumor lymphangiogenesis promotes 
tumor escape of host immunity.
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